8-K: Day One's OJEMDA Shows Durable 3-Year Efficacy in pLGG

Day One Biopharmaceuticals announced positive three-year follow-up data for OJEMDA (tovorafenib) in pediatric low-grade glioma, alongside strong Q3 2025 revenue growth and raised full-year guidance.

Summary

• Day One Biopharmaceuticals reported updated three-year results from the pivotal Phase 2 FIREFLY-1 trial for OJEMDA (tovorafenib) in relapsed or refractory pediatric low-grade glioma (pLGG).
• The median study duration for Arm 1 patients was 40.6 months, with 58% (44 out of 76 patients) completing 26 or more cycles of treatment (approximately 24 months).
• The overall response rate (ORR) was 53% (40 out of 76 patients), with a median duration of response (DOR) of 19.4 months (95% CI [13.8-27.2]).
• The median time to next treatment (TTNT) was 42.6 months (95% CI [36.7-NE]), indicating patients spent significant time off subsequent therapy.
• Among 39 patients entering a treatment-free observation period, 77% (30 out of 39) remained treatment-free for at least 12 months, and the median treatment-free interval was not reached.
• Tumor rebound was minimal in the first 6 months off therapy, with 31% of patients experiencing a 25% increase in tumor size from the last scan prior to the last dose.
• Eight patients received retreatment with tovorafenib, showing a median retreatment duration of 9 months and a median maximum tumor reduction of 38.3%.
• No new safety signals were identified in the updated three-year analysis; common Grade 3 or higher adverse events included decreased growth velocity, anemia, and increased blood creatine phosphokinase.
• OJEMDA net product revenue for Q3 2025 was $38.5 million, representing a 15% growth over Q2 2025.
• Year-to-date 2025 OJEMDA net product revenue reached $102.6 million, exceeding full-year 2024 by approximately 89%.
• The company raised its 2025 net product revenue guidance for OJEMDA to $145 million $150 million.
• Cash, cash equivalents, and short-term investments stood at $451.6 million as of September 30, 2025.
• The pipeline includes the ongoing Phase 3 FIREFLY-2 trial for tovorafenib in front-line pLGG, with enrollment completion expected in 1H 2026.
• Day One announced the acquisition of Emi-Le (B7-H4-Targeted ADC) and reported that the first dose cohort for DAY301 (PTK7-Targeted ADC) was cleared in January 2025.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical data for OJEMDA, demonstrating durable efficacy and a long treatment-free interval, which is a significant benefit for pediatric cancer patients. Strong commercial performance, evidenced by double-digit revenue growth and raised guidance, further enhances the positive outlook. The expansion of the pipeline with promising ADC programs adds to the long-term value proposition. While there was a net loss, it's understood in the context of R&D and commercialization for a growing biopharmaceutical company, and the overall news is overwhelmingly positive for the drug's profile and company's trajectory.

Positives

• OJEMDA demonstrated deep and durable responses with an overall response rate of 53% and a median duration of response of 19.4 months.
• The median time to next treatment (TTNT) of 42.6 months highlights the long-term clinical benefit and ability for patients to remain off subsequent therapies for extended periods.
• A significant proportion of patients (77%) remained treatment-free for at least 12 months after completing primary tovorafenib treatment, with minimal tumor rebound.
• Retreatment with tovorafenib showed activity, with a median maximum tumor reduction of 38.3% in patients who reinitiated therapy.
• No new safety signals were identified in the three-year follow-up, reinforcing the favorable safety profile of OJEMDA.
• Strong commercial performance for OJEMDA, with Q3 2025 net product revenue of $38.5 million, a 15% increase over Q2 2025.
• Year-to-date 2025 OJEMDA net product revenue of $102.6 million significantly surpassed full-year 2024 revenue by 89%.
• The company raised its 2025 net product revenue guidance to $145 million $150 million, indicating confidence in continued growth.
• Expansion of the pipeline through the acquisition of Emi-Le (B7-H4-Targeted ADC) and progress with DAY301 (PTK7-Targeted ADC) provides future growth opportunities.
• High prescriber confidence is building, with increasing second-line adoption and strong persistency rates for OJEMDA.

Negatives

• The company reported a net loss of $19.7 million for Q3 2025, compared to a net income of $37.0 million in Q3 2024, though the prior year included significant license revenue and a PRV sale.

Risks

• Ability to obtain regulatory approval for, and commercialize, tovorafenib.
• Future results of operations and financial position may differ from expectations.
• Uncertainties regarding business strategy, market size, and potential growth opportunities.
• Risks associated with nonclinical and clinical development activities, including efficacy and safety profiles of product candidates.
• Ability to maintain and recognize the benefits of certain designations received by product candidates (e.g., Breakthrough Therapy, Rare Pediatric Disease).
• Timing and results of nonclinical studies and clinical trials may vary.
• Risks related to commercial collaboration with third parties and the ability to recognize milestone and royalty payments.
• Expected impact of global business or macroeconomic conditions, including inflation, rising interest rates, cybersecurity incidents, instability in the global banking system, government shutdowns, uncertainty with respect to the federal budget, and geopolitical conflicts (e.g., Israel and Ukraine) on operations.
• Sufficiency of cash, cash equivalents, and investments to fund operations.
• Ability to protect intellectual property.

Future Outlook

The company expects continued revenue growth from OJEMDA globally and aims for indication expansion in front-line pLGG with the FIREFLY-2 trial, with enrollment completion anticipated in the first half of 2026. An EMA regulatory decision for OJEMDA is expected in 2026. Day One also plans to generate clinical proof-of-concept data for its DAY301 program and fund pipeline expansion, including the recently acquired Emi-Le program. The company is raising its 2025 net product revenue guidance for OJEMDA to $145 million $150 million, reflecting confidence in ongoing commercial performance.

Management Comments

• "We are excited by these updated three-year data showing that patients taking tovorafenib were able to spend meaningful time off therapy, with the option to retreat as needed." Elly Barry, MD, Chief Medical Officer of Day One.
• "These findings highlight the potential for a treatment approach to help support patients through the long-term course of their disease and further support our view that tovorafenib has the potential to become the second line standard of care in pLGG." Elly Barry, MD, Chief Medical Officer of Day One.
• "These three-year data showed that patients were able to maintain disease control during extended periods off therapy, with the option to reinitiate tovorafenib treatment if clinically indicated. This approach has the potential to offer patients and their families meaningful time away from treatment." Dr. Cassie Kline, Director of Clinical Research in the Division of Neuro-Oncology at the Children's Hospital of Philadelphia.

Industry Context

The announcement reinforces Day One's position in the pediatric oncology market, particularly for pLGG, a rare and chronic brain tumor with significant unmet needs. The long median time to next treatment and the ability for patients to remain treatment-free for extended periods with OJEMDA represent a significant advancement, potentially shifting the standard of care in the second-line setting. The expansion into front-line pLGG with the FIREFLY-2 trial and the addition of two antibody-drug conjugate (ADC) programs (Emi-Le and DAY301) demonstrate a strategic focus on targeted therapies for life-threatening diseases across both pediatric and adult populations, aligning with broader industry trends towards precision medicine and diversified oncology pipelines.

Comparison to Industry Standards

• For the majority of patients with pLGG in the relapsed setting, there was no standard of care and, until recently, no approved therapies. OJEMDA's demonstrated efficacy and durability address a critical unmet need.
• The median time to next treatment (TTNT) of 42.6 months for OJEMDA in relapsed/refractory pLGG is a strong indicator of sustained disease control, potentially outperforming traditional chemotherapy regimens which often lead to earlier progression and need for subsequent treatments.
• The high percentage of patients (77%) remaining treatment-free for at least 12 months post-OJEMDA treatment suggests a significant improvement in quality of life compared to continuous or frequently interrupted treatment schedules common in chronic pediatric cancers.
• The observed retreatment activity with OJEMDA, showing a median maximum tumor reduction of 38.3%, provides a valuable option for managing disease recurrence, which is a common challenge in pLGG where patients often undergo multiple lines of systemic therapy.

Stakeholder Impact

• **Shareholders:** Likely positive impact due to strong clinical data, robust commercial performance, raised revenue guidance, and pipeline expansion, suggesting increased future value and market confidence.
• **Patients (pLGG):** Highly positive impact, as OJEMDA offers durable disease control, extended treatment-free periods, and a favorable safety profile, potentially improving quality of life and long-term outcomes.
• **Healthcare Providers:** Provides strong evidence for OJEMDA as a potential second-line standard of care, offering a valuable treatment option for pLGG patients with BRAF alterations.
• **Employees:** Positive impact from company growth, successful drug performance, and pipeline expansion, potentially leading to job security and growth opportunities.
• **Regulatory Authorities:** The detailed three-year data further supports the clinical benefit of OJEMDA, which was initially approved under accelerated approval, potentially aiding in verification of clinical benefit in confirmatory trials.

Next Steps

• Continue commercialization efforts for OJEMDA globally to drive revenue growth.
• Complete enrollment for the Phase 3 FIREFLY-2 trial for tovorafenib in front-line pLGG, expected in 1H 2026.
• Await EMA regulatory decision for OJEMDA, expected in 2026.
• Generate clinical proof-of-concept data for the DAY301 program.
• Advance the Emi-Le (B7-H4-Targeted ADC) program following the acquisition.
• Present and publish the 3-year FIREFLY-1 data at scientific conferences and in journals.
• Support physicians and patients to optimize their experience on OJEMDA, including effective adverse event management and reimbursement support.
• Increase depth of prescribing by expanding physicians' belief in which patients will benefit from OJEMDA and using it in the second-line setting.
• Expand prescriber base by converting non-users into first-time adopters of OJEMDA.

Key Dates

Recommendation

The filing presents compelling evidence of OJEMDA's long-term efficacy and safety, with a median time to next treatment exceeding 3.5 years and a high percentage of patients remaining treatment-free for over a year. This durable clinical benefit, coupled with strong commercial execution leading to double-digit revenue growth and a significant increase in full-year guidance, indicates robust market adoption and future revenue potential. The strategic expansion of the pipeline with two promising ADC programs further de-risks the company's long-term growth trajectory. Despite a net loss, the underlying operational performance and clinical advancements are exceptionally strong, positioning Day One Biopharmaceuticals for substantial future value creation. This combination of clinical success, commercial momentum, and pipeline growth makes it a strong buy for investors.

Keywords

Day One Biopharmaceuticals, OJEMDA, tovorafenib, pediatric low-grade glioma, pLGG, BRAF fusion, BRAF V600 mutation, FIREFLY-1 trial, Phase 2 clinical trial, oncology, neuro-oncology, targeted therapy, biopharmaceutical, clinical data, drug development, cancer treatment, antibody-drug conjugate, ADC, Emi-Le, DAY301, financial results, revenue guidance